Peninsula drug maker’s stock blows up after 2nd nasal migraine drug flop


The company was developing a nasal dry-powder spray, and it thinks study data show the drug-device will work — but another company likely will take it the rest of the way.

Previous Hawaii to receive more than $4.7M from multistate settlement with Google
Next Venture capital firm General Catalyst to partner with UC Davis Health on digital medicine